The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

Mays Cancer Center: Targeting certain molecular interactions could yield new strategies for treating prostate cancer

Retrieved on: 
Friday, October 20, 2023
United States Secretary of Education, Research, Longevity, Duke Cancer Institute, Ageing, Molecular biology, Duke University, Nursing, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Dentistry, Doctor of Philosophy, Health, Prostate cancer, Protein, Cell, California Institute for Regenerative Medicine, Chromatin, National Cancer Institute, Male, Biotechnology, Sam, Disease, Medicine, University of Texas Health Science Center at San Antonio, Teaching, School, University, UT Health San Antonio Cancer Center, Public, Office of Inspector General, U.S. Department of Health and Human Services, University of Texas System, Molecular medicine, AR, Patient, Chromosome, SAN, DNA, Pharmaceutical industry, Vaccine, Advertising, Molecular Cell, Cancer

SAN ANTONIO, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases.

Key Points: 
  • SAN ANTONIO, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases.
  • "Our results provide molecular insights for potential therapeutic strategies to treat prostate cancer and other AR-involved diseases by targeting AR multivalent interactions," said Zhijie "Jason" Liu, PhD, associate professor and CPRIT Scholar in Cancer Research with Mays Cancer Center and the Institute of Biotechnology of the Department of Molecular Medicine at UT Health San Antonio.
  • The Mays Cancer Center at UT Health San Antonio is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration

Retrieved on: 
Tuesday, April 25, 2023
The Ride to Conquer Cancer, Sidney Kimmel, Sreyashi Jhumki Basu, GBM, Research group, Ovarian cancer, Pancreatic cancer, Cancer, Research, Koch Institute, MIT, CD73, Genomics, The Institute, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Associate, Science, Physician, Sidney Kimmel Comprehensive Cancer Center, University, Escape Room, Drug development, Knowledge, Koch Institute for Integrative Cancer Research, TeamLab (art collective), Johns Hopkins, Break, Tumor microenvironment, Nanobiotechnology, Vaccine, Medical imaging

CAMBRIDGE, Mass., April 25, 2023 /PRNewswire/ -- Break Through Cancer, a foundation designed to find new solutions to some of the most intractable challenges in cancer, has named four individuals as Break Through Cancer Scientists—Neelkanth Bardhan, Sreyashi Basu, Paola A. Guerrero, and Thomas R. Pisanic II. They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.

Key Points: 
  • They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.
  • The Break Through Cancer Scientists were carefully selected based on their expertise in early diagnostics, single cell genomics data and materials science, and specific types of cancer.
  • "These newly named Break Through Cancer Scientists have cultivated stellar reputations and demonstrated outstanding success in working across scientific disciplines to establish a collaborative environment.
  • A Research Group Leader at The University of Texas MD Anderson Cancer Center's Pancreatic Cancer Research Center, Paola leads innovative research on patient-derived models and biospecimens.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 27, 2023
Myelodysplastic syndrome, Abstract, Rituximab, AACR, University, Cell death, ASH, Cancer prevention, Sarcoma, Multiple myeloma, Drug discovery, Clinical trial, Bone marrow, Lenalidomide, NHL, Chronic myelomonocytic leukemia, American Association for Cancer Research, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Research, MD Anderson Cancer Center, Monroe Dunaway Anderson, Salinicola salarius, Azacitidine, Protein, Acquisition, Patent, Patient, Mouse, Research institute, Ewing sarcoma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, Factorization of polynomials, Food, Cancer Prevention and Research Institute of Texas, Cryptocurrency, Video game, Pharmaceutical industry, Rail freight transport, Vaccine

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2022 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $12.1 million as of December 31, 2022, compared with $29.2 million as of December 31, 2021.
  • Research and development expenses were $4.7 million in the fourth quarter of 2022, compared with $2.7 million in the fourth quarter of 2021.
  • As of December 31, 2022, Salarius had cash, cash equivalents and restricted cash of $12.1 million, compared with $29.2 million as of December 31, 2021.
  • Current cash and cash equivalents are expected to fund the company’s planned operations into the fourth quarter of 2023.

Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award

Retrieved on: 
Tuesday, August 2, 2022
Health, Stem Cells, Health Technology, Other Health, Managed Care, General Health, Diagnosis, Biomedical sciences, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, ASH, Inclusion, Disorder, 2009 Davis Cup, LinkedIn, Hematology-Oncology and Stem Cell Transplantation Research Center, Education, Center for International Blood and Marrow Transplant Research, Society, Exposition, Faculty, Program, Leadership, Diversity, MCW, Center, Physician, Graduate School of Biomedical Sciences, Twitter, HCT, Quality of life, MD Anderson Cancer Center, Survival, Medical college, Transplant, Medical College of Wisconsin, Medicine, National Marrow Donor Program, MPH, Health, American Society of Hematology, Patient, NMDP, Hematopoietic stem cell transplantation, UT, Pharmaceutical industry, Medical device, Dentistry, Hematology, Research, Blood, Facebook, MD

The Center for International Blood and Marrow Transplantation (CIBMTR), is delighted to announce that Owhofasa Agbedia, MD, MPH, has been selected to receive the ASH-CIBMTR-ASTCT Career Development Award.

Key Points: 
  • The Center for International Blood and Marrow Transplantation (CIBMTR), is delighted to announce that Owhofasa Agbedia, MD, MPH, has been selected to receive the ASH-CIBMTR-ASTCT Career Development Award.
  • The award is part of a program to increase racial and ethnic diversity in the next generation of medical professionals.
  • We believe that diversity, equity, and inclusion in our field are essential to innovation and eliminating health care disparities.
  • Along with our partner organizations, the CIBMTR is committed to supporting the career development of our next generation, particularly those with diverse backgrounds.

Dr. Owhofasa Agbedia to Receive the 2021 ASH-CIBMTR-ASTCT Career Development Award

Retrieved on: 
Wednesday, June 22, 2022
UT, Education, MD Anderson Cancer Center, Graduate School of Biomedical Sciences, Transplant, 2009 Davis Cup, ASH, Society, Travel, National Marrow Donor Program, Fred Hutchinson Cancer Research Center, Association, Inclusion, Faculty, Hematopoietic stem cell transplantation, Research, Tandem, Physician, Hematology-Oncology and Stem Cell Transplantation Research Center, Diversity, Minority, Workforce, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Medical College of Wisconsin, Exposition, Center for International Blood and Marrow Transplant Research, Medical college, Twitter, Biomedical sciences, Medicine, Partnership, MPH, Health, Center, Blood, GLOBE, Dentistry, Hematology, MD

This new award is a part of the ASH Minority Hematology Fellow Award (MHFA) program, which supports early-career researchers from minority groups historically underrepresented in medicine.

Key Points: 
  • This new award is a part of the ASH Minority Hematology Fellow Award (MHFA) program, which supports early-career researchers from minority groups historically underrepresented in medicine.
  • This new partnership award is exclusively for fellows pursuing careers in hematopoietic stem cell transplantation and cellular therapy.
  • Additionally, as part of this award, Dr. Agbedia will receive opportunities from ASTCT and CIBMTR.
  • The Career Development Award is also part of ASTCT's award expansion, which includes a New Investigator Award for Underrepresented Minorities and additional Travel Grants for the Tandem Meetings: Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR.

Frontier Medicines Announces Prominent Oncologist Dr. Scott Kopetz Joins its Scientific Advisory Board

Retrieved on: 
Tuesday, June 21, 2022
Colon cancer staging, Internal medicine, Department, Duke University Hospital, The Lancet, FACP, Journal, Vanderbilt University, JAMA, CEO, Monroe Dunaway Anderson, Cancer, Precision medicine, Coronavirus Scientific Advisory Board (Turkey), Proteome, Oncology, American Association for Cancer Research, LinkedIn, The New England Journal of Medicine, Disease, University, Colorectal cancer, GLOBE, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Johns Hopkins School of Medicine, Frontier, Biomedical sciences, MD Anderson Cancer Center, BRAF, SAB, Mutation, Twitter, Medicine, Patient, Doctor of Philosophy, KRAS, Journal of Clinical Oncology, SAN, Nature Medicine, Machine learning, Pharmaceutical industry, Lancet

Dr. Kopetz joined MD Anderson in 2006 and is Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology.

Key Points: 
  • Dr. Kopetz joined MD Anderson in 2006 and is Professor and Deputy Chair in the Department of Gastrointestinal Medical Oncology.
  • Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable.
  • Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer.
  • For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter .

INFOBAE.COM: Houston doctors and researchers that are making the biggest international impact according to the KOLs list - Most of them are women

Retrieved on: 
Wednesday, May 11, 2022
Division, Department, KOL, Woman, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, MD Anderson Cancer Center, Physician, Harris Health System, University of Ottawa Heart Institute, COVID, Baylor College of Medicine, University of Texas at Austin, Internet, Cardiology, Houston Methodist Hospital, Haematopoietic system, Patient, Lists of people executed in the United States, Technology, Dentistry, Endocrinology

SANTA BARBARA, Calif., May 11, 2022 /PRNewswire/ --The work of Houston doctors and researchers is getting international attention.

Key Points: 
  • SANTA BARBARA, Calif., May 11, 2022 /PRNewswire/ --The work of Houston doctors and researchers is getting international attention.
  • The most researched areas in Houston after COVID are Oncology, Cardiology, and Endocrinology.
  • According to the KOLs list, the leading institutions are The University Of Texas MD Anderson, Houston Methodist, Harris Health System, Heart Institute, and Baylor College Of Medicine.
  • In healthcare, KOLs play an essential role in shaping the discourse around key issues and helping to drive change within the health system.

INFOBAE.COM: Houston doctors and researchers that are making the biggest international impact according to the KOLs list - Most of them are women

Retrieved on: 
Wednesday, May 11, 2022
Division, Department, KOL, Woman, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, MD Anderson Cancer Center, Physician, Harris Health System, University of Ottawa Heart Institute, COVID, Baylor College of Medicine, University of Texas at Austin, Internet, Cardiology, Houston Methodist Hospital, Haematopoietic system, Patient, Lists of people executed in the United States, Technology, Dentistry, Endocrinology

SANTA BARBARA, Calif., May 11, 2022 /PRNewswire/ --The work of Houston doctors and researchers is getting international attention.

Key Points: 
  • SANTA BARBARA, Calif., May 11, 2022 /PRNewswire/ --The work of Houston doctors and researchers is getting international attention.
  • The most researched areas in Houston after COVID are Oncology, Cardiology, and Endocrinology.
  • According to the KOLs list, the leading institutions are The University Of Texas MD Anderson, Houston Methodist, Harris Health System, Heart Institute, and Baylor College Of Medicine.
  • In healthcare, KOLs play an essential role in shaping the discourse around key issues and helping to drive change within the health system.